Sweden Brain Cancer drugs market Segmented by Drug Class (Temozolomide, Carmustine, Cisplatin, Bevacizumab, Geftinib and Erlotinib), Therapy type (Chemotherapy, Immunotherapy, Targeted therapy and others) and Distribution channels (Hospital pharmacies, retail pharmacies, online pharmacies and others) Growth, Trends, and Forecasts (2020 to 2028)
- Published Date: 2022-12-13
- Report ID: 141618
- Pages: 200
-
Format:
Report Overview
The Global Brain Cancer drugs market size stood at USD 2.83 billion in 2021 and is expected to rise to USD 5.64 billion by the end of 2028 exhibiting a CAGR of approximately 10.4% during the forecast period.
Brain cancer arises from abnormal proliferation of cells in the brain which occurs as a result of exposure to ionising radiation or other genetic mutations in the body. This is associated with frequent headaches, double vision, hearing and speech abnormalities which impede with the quality of life. This creates opportunities for the pharmaceutical manufacturers to couple new advances in technology with existing treatment modalities to introduce new drugs into the market.
Market Drivers
Brain Cancer drugs market in Sweden is mainly driven by the growing incidence and prevalence of neurological disorders. Neurological disorders are highly prevalent owing to their longer life expectancy. This aspect, coupled with the rising geriatric population is promising in terms of market growth. New growth opportunities are on the rise with new drugs in the pipeline for paediatric patients.
1. Sweden Brain Cancer Drugs Market Overview.....................
A. Market Size
2. Market Growth Drivers.
A. Rise in incidence and prevalence of Neurological disorders
B. Rise in Geriatric Population
C. Increased Per Capita Spending on Healthcare
D. New drugs in the pipeline for paediatric patients
3. Major types of Brain Cancers...............................................................................
A. Meningioma
B. Pituitary tumours
C. Glioblastoma
D. Others
4. Market Segmentation.................................................
A. Drug class
I. Temozolomide
II. Carmustine
III. Cisplatin
IV. Bevacizumab
V. Geftinib
VI. Erlotinib
B. Type of Therapy
I. Chemotherapy
II. Immunotherapy
III. Targeted therapy
IV. Others
C. Distribution Channel
I. Hospital pharmacies
II. Retail pharmacies
III. Online pharmacies
IV. Others
5. Brain Cancer Major Drugs Market Share..........
A. Market Analysis, Insights and Forecast By Revenue
6. Competitive Landscape....
A. Major Players
B. Products in Pipeline
7. Key Company Profiles..
8. Healthcare Policies and Regulatory Landscape
A. Policy changes and Reimbursement scenario
9. Factors Driving Future Growth.....
A. New Trends and Development of Brain Cancer drugs market
B. Future Opportunities
10. Conclusion.............................................................................................................
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
